Literature DB >> 24140972

Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis.

Andrea Messori1, Valeria Fadda, Dario Maratea, Sabrina Trippoli, Claudio Marinai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24140972     DOI： 10.1093/cid/cit588

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

Review 1.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

2.  Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban.

Authors:  Andrea Messori; Dario Maratea; Valeria Fadda; Sabrina Trippoli
Journal:  Eur J Clin Pharmacol       Date:  2014-01-23       Impact factor: 2.953

3.  Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.

Authors:  Heba A Mohamed; Rasha R Radwan; Amany I Raafat; Amr El-Hag Ali
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

Review 4.  Design of amphotericin B oral formulation for antifungal therapy.

Authors:  Min Liu; Meiwan Chen; Zhiwen Yang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites.

Authors:  William Devine; Sarah M Thomas; Jessey Erath; Kelly A Bachovchin; Patricia J Lee; Susan E Leed; Ana Rodriguez; Richard J Sciotti; Kojo Mensa-Wilmot; Michael P Pollastri
Journal:  ACS Med Chem Lett       Date:  2017-02-05       Impact factor: 4.345
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.